• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Keytruda

yellow road to bright light
Biotech

Rakuten lights path to 2028 FDA filing with fresh $100M raise

Rakuten has added to its tally of megarounds, pocketing $100 million to push its lead light-based cancer therapy toward an approval filing in 2028.
Nick Paul Taylor Jan 7, 2026 9:43am
cancer ribbons world cancer day cancer awareness

Promega wins FDA OK as Keytruda-Lenvima companion diagnostic

Nov 13, 2025 4:00am
Pfizer

Pfizer lays out its PD-1xVEGF bispecific research strategy

Nov 11, 2025 11:43am
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am
green light go go ahead advance yes streetlight

Moderna posts melanoma data behind decision to say 'I do' to IDO

Oct 13, 2025 5:15am
next step ladder climb succeed win

PDS reports 39 months OS in phase 2 head and neck cancer trial

Aug 25, 2025 9:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings